Ankara City Hospital, Clinic of Rheumatology, Ankara, Turkey.
Department of Internal Medicine, Division of Rheumatology, Yıldırım Beyazıt University Medical School, Ankara, Turkey.
Int J Rheum Dis. 2022 Jul;25(7):787-794. doi: 10.1111/1756-185X.14349. Epub 2022 Jun 1.
To determine frequency of adverse events and attacks related to vaccination in recipients of CoronaVac and BNT162b2 in familial Mediterranean fever (FMF) patients, and to search whether history of prior COVID-19 or a booster dose increases occurrence of adverse events/attacks.
FMF patients were surveyed for administration of any COVID-19 vaccine and vaccine-related adverse events or FMF attacks. Demographic, clinical, vaccine-related data, history of COVID-19 infection before or after vaccination, adherence to FMF treatment during vaccination were collected.
A total of 161 vaccinated FMF patients were included. Ninety-three patients out of 161 had reported suffering from an adverse event/attack after a vaccine dose. There were 54.7% of BNT162b2 recipients who reported any adverse event after any vaccine dose in comparison to 29.9% of CoronaVac recipients (P < .001). There were 22.2% of BNT162b2 recipients who reported suffering from a FMF attack within 1 month after vaccination in comparison to 19.4% of CoronaVac recipients (P = .653). When patients with or without adverse event/attack were compared, no significant differences were observed in means of demographics, comorbid diseases, disease duration, total vaccine doses, or treatments adhered to for FMF. Rates of adverse events/attacks were similar between patients with and without prior COVID-19. In booster recipients, adverse events/attacks were most frequent after the booster dose.
A considerable number of FMF patients suffered from vaccine-related adverse events/attacks, particularly with BNT162b2. No serious events or mortalities due to vaccination were detected. Demographics, clinical characteristics and prior history of vaccination did not significantly affect these results. We observed an increased rate of adverse events/attacks with booster dose administration.
确定在家族性地中海热（FMF）患者中接种科兴和国药疫苗后与疫苗接种相关的不良反应和攻击的频率，并探讨既往 COVID-19 感染史或加强针是否会增加不良反应/攻击的发生。
对 FMF 患者进行了有关任何 COVID-19 疫苗接种和疫苗相关不良反应或 FMF 发作的调查。收集了人口统计学、临床、疫苗相关数据、接种前后 COVID-19 感染史、接种期间 FMF 治疗的依从性等信息。
共纳入 161 名接种疫苗的 FMF 患者。161 名患者中有 93 名报告在接种一剂疫苗后出现不良反应/攻击。与科兴疫苗相比，BNT162b2 疫苗接种后任何剂量报告任何不良反应的患者比例为 54.7%，而科兴疫苗为 29.9%（P<0.001）。与科兴疫苗相比，BNT162b2 疫苗接种后 1 个月内报告 FMF 发作的患者比例为 22.2%，而科兴疫苗为 19.4%（P=0.653）。比较有或无不良反应/攻击的患者，在人口统计学、合并症、疾病持续时间、总疫苗剂量或 FMF 治疗依从性方面无显著差异。有或无既往 COVID-19 感染史的患者不良反应/攻击发生率相似。在加强针接种者中，不良反应/攻击最常发生在加强针接种后。
相当数量的 FMF 患者出现与疫苗接种相关的不良反应/攻击，尤其是 BNT162b2 疫苗。未发现因接种疫苗而发生严重事件或死亡。接种疫苗前的人口统计学、临床特征和既往史对这些结果没有显著影响。我们观察到加强针接种后不良反应/攻击的发生率增加。
